Literature DB >> 18245198

Selection of linezolid-resistant Enterococcus faecium in an in vitro dynamic model: protective effect of doxycycline.

Stephen H Zinner1, Deborah Gilbert, Irene Yu Lubenko, Kenneth Greer, Alexander A Firsov.   

Abstract

OBJECTIVES: To relate the enrichment of linezolid-resistant Enterococcus faecium with linezolid pharmacokinetics, the pharmacodynamics of linezolid and its ability to prevent the selection of resistant mutants were studied in an in vitro model that simulates antibiotic concentrations in and out of the mutant selection window (MSW), i.e. the concentration range from the MIC to the mutant prevention concentration (MPC).
METHODS: A clinical isolate of E. faecium (MIC 1.8 mg/L and MPC 7 mg/L) at a starting inoculum of 8 log cfu/mL was exposed to twice-daily linezolid, alone and in combination with once-daily doxycycline (MIC 0.2 mg/L and MPC 3.4 mg/L), for 3 consecutive days in a hollow-fibre two-compartment model.
RESULTS: The ratios of 24 h area under the curve (AUC24) to MIC of linezolid were estimated at 70, 100 and 230 h and those of doxycycline were estimated at 230 and 720 h. At the two lower AUC24/MIC ratios of linezolid given alone, E. faecium resistant to 2 x MIC-16 x MIC and 2 x MIC-8 x MIC of linezolid, respectively, were selectively enriched with a concomitant slight loss in susceptibility. Neither growth on linezolid-containing media nor changes in susceptibility occurred at the high AUC24/MIC ratio. A similar protective effect was observed with the minimal AUC24/MIC ratio of linezolid (70 h) combined with doxycycline at an AUC24/MIC of 230 h.
CONCLUSIONS: This study suggests that selection of linezolid-resistant enterococci can be predicted from the MSW concept and can be prevented by linezolid given in combination with doxycycline, each at suboptimal AUC24/MIC ratios.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18245198     DOI: 10.1093/jac/dkm542

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

1.  In vitro resistance studies with bacteria that exhibit low mutation frequencies: prediction of "antimutant" linezolid concentrations using a mixed inoculum containing both susceptible and resistant Staphylococcus aureus.

Authors:  Alexander A Firsov; Maria V Golikova; Elena N Strukova; Yury A Portnoy; Andrey V Romanov; Mikhail V Edelstein; Stephen H Zinner
Journal:  Antimicrob Agents Chemother       Date:  2014-12-01       Impact factor: 5.191

Review 2.  Management of multidrug-resistant enterococcal infections.

Authors:  C A Arias; G A Contreras; B E Murray
Journal:  Clin Microbiol Infect       Date:  2010-06       Impact factor: 8.067

3.  Activity of linezolid in an in vitro pharmacokinetic-pharmacodynamic model using different dosages and Staphylococcus aureus and Enterococcus faecalis strains with and without a hypermutator phenotype.

Authors:  Boubakar B Ba; Corinne Arpin; Branly Bikie Bi Nso; Véronique Dubois; Marie-Claude Saux; Claudine Quentin
Journal:  Antimicrob Agents Chemother       Date:  2010-01-25       Impact factor: 5.191

4.  In vivo evaluation of mutant selection window of cefquinome against Escherichia coli in piglet tissue-cage model.

Authors:  Bingxu Zhang; Xiaoyan Gu; Yafei Li; Xiaohong Li; Mengxiao Gu; Nan Zhang; Xiangguang Shen; Huanzhong Ding
Journal:  BMC Vet Res       Date:  2014-12-16       Impact factor: 2.741

5.  Relationship between danofloxacin PK/PD parameters and emergence and mechanism of resistance of Mycoplasma gallisepticum in In Vitro model.

Authors:  Nan Zhang; Yuzhi Wu; Zilong Huang; Chuanzhen Zhang; Longfei Zhang; Qinren Cai; Xiangguang Shen; Hongxia Jiang; Huanzhong Ding
Journal:  PLoS One       Date:  2018-08-29       Impact factor: 3.240

6.  In vitro activity and post-antibiotic effects of linezolid in combination with fosfomycin against clinical isolates of Staphylococcus aureus.

Authors:  Hao Chen; Lan Li; Yanyan Liu; Maomao Wu; Shuangli Xu; Guijun Zhang; Caifen Qi; Yan Du; Mingli Wang; Jiabin Li; Xiaohui Huang
Journal:  Infect Drug Resist       Date:  2018-11-01       Impact factor: 4.003

7.  Synergistic Combination of Linezolid and Fosfomycin Closing Each Other's Mutant Selection Window to Prevent Enterococcal Resistance.

Authors:  Lifang Jiang; Na Xie; Mingtao Chen; Yanyan Liu; Shuaishuai Wang; Jun Mao; Jiabin Li; Xiaohui Huang
Journal:  Front Microbiol       Date:  2021-02-09       Impact factor: 5.640

8.  Pharmacokinetic/Pharmacodynamic Integration to Evaluate the Changes in Susceptibility of Actinobacillus pleuropneumoniae After Repeated Administration of Danofloxacin.

Authors:  Longfei Zhang; Zheng Kang; Lihua Yao; Xiaoyan Gu; Zilong Huang; Qinren Cai; Xiangguang Shen; Huanzhong Ding
Journal:  Front Microbiol       Date:  2018-10-10       Impact factor: 5.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.